uniQure said on June 17, 2026 that, following a Type B meeting, the US Food and Drug Administration indicated the approximately three-year analysis from its phase 1/2 programme of AMT-130 can serve as the primary basis of a Biologics License Application for accelerated approval in Huntington's disease. In its second-quarter statement on July 29, 2026, the company said official meeting minutes received in July confirmed that the agency and the company had aligned that such a submission based on existing clinical data is reasonable, that the FDA wants agreement on the design of a confirmatory study before the filing goes in, and that the application remains on track for the third quarter of 2026. A parallel submission to the United Kingdom's Medicines and Healthcare products Regulatory Agency is planned for the same quarter.

The evidence is a single small early-phase programme. The registration record for the US study (NCT04120493) describes a phase 1/2, multicentre, first-in-human trial in adults aged 25 to 65 with early manifest disease, in which AMT-130 is delivered once by MRI-guided, convection-enhanced stereotactic neurosurgery into the striatum; the first cohorts were randomised, double-blind and sham-controlled, with later cohorts open-label. In topline results announced on September 24, 2025 (data cutoff June 30, 2025), uniQure reported that 29 treated patients had been analysed (17 high dose, 12 low dose), of whom 12 per dose group had reached 36 months. Against a propensity score-matched external control drawn from the Enroll-HD natural history dataset (940 patients for the high-dose comparison), high-dose patients showed a 75 percent slowing of progression on the composite Unified Huntington's Disease Rating Scale, the study's primary endpoint (mean change from baseline -0.38 versus -1.52; p=0.003), a 60 percent slowing on Total Functional Capacity (p=0.033) and a mean cerebrospinal fluid neurofilament light reduction of 8.2 percent from baseline at 36 months. These are company-reported topline figures, and the three-year comparison is with a statistical model of untreated patients, not with a concurrent randomised group.

That comparison is precisely what regulators argued over. On November 3, 2025 uniQure said the FDA appeared to no longer agree that the phase 1/2 data against an external control could provide the primary evidence for a filing, a position confirmed in final minutes disclosed on December 4, 2025. On March 2, 2026 the company said the agency, after a Type A meeting, could not agree the data were sufficient and strongly recommended a prospective, randomised, double-blind, sham surgery-controlled study. The June 2026 position reverses that for filing purposes only: accelerated approval rests on an intermediate endpoint and still requires a confirmatory trial, which the FDA has indicated may use a concurrent control on standard-of-care therapy rather than a sham procedure. AMT-130 holds Regenerative Medicine Advanced Therapy designation, granted in May 2024, and Breakthrough Therapy designation, granted in April 2025.

On safety, uniQure reported the therapy was generally well tolerated at both doses, with no new drug-related serious adverse events since December 2022 and the most common adverse events related to the surgical administration procedure, all of which resolved. No therapy has been approved anywhere to slow Huntington's disease, an inherited condition that brings movement, behavioural and cognitive decline, so an approval would be a first for the field and, if it holds, the first built mainly on a small externally controlled surgical trial. Neither the FDA nor the MHRA has received the application yet, and neither has ruled on it.